Xiaojie Zhang

Dr. Xiaojie Zhang

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2024 in Microbiological Research
Verified
Journal Article
Closed access
SQShiyan Qu
Shiyan Qu
ZYZijin Yu
Zijin Yu
YZYaxuan Zhou
Yaxuan Zhou
SWShiyi Wang
Shiyi Wang
MJMinqi Jia
Minqi Jia
XZXiaojie Zhang
Xiaojie Zhang

4 March 2022 in Critical Reviews in Microbiology
Verified
Journal Article
Open access
RXRuiling Xu
Ruiling Xu
YZYuxuan Zhang
Yuxuan Zhang
SCShurui Chen
Shurui Chen
YZYaohui Zeng
Yaohui Zeng
XFXuan Fu
Xuan Fu
XZXiaojie Zhang
Xiaojie Zhang
The role of Akkermansia muciniphila, one of the most abundant microorganisms of the intestinal microbiota, has been studied extensively in metabolic diseases, such as obesity and diabetes. It is considered a next-generation probiotic microorganism. Although its mechanism of action has not been fully elucidated, accumulating evidence indicates the important role of A. muciniphila in brain functions via the gut-brain axis and its potential as a therapeutic target in various neuropsychiatric disorders. However, only a limited number of studies, particularly clinical studies, have directly assessed the therapeutic effects of A. muciniphila interventions in these disorders. This is the first review to discuss the comprehensive mechanism of A. muciniphila in the gut-brain axis via the protection of the intestinal mucosal barrier and modulation of the immune system and metabolites, such as short-chain fatty acids, amino acids, and amino acid derivatives. Additionally, the role of A. muciniphila and its therapeutic potential in various neuropsychiatric disorders, including Alzheimer’s disease and cognitive deficit, amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis, have been discussed. The review suggests the potential role of A. muciniphila in healthy brain functions.

5 September 2023 in Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
HGHuijuan Guo
Huijuan Guo
XLXinxu Liu
Xinxu Liu
TCTi Chen
Ti Chen
XWXiaoping Wang
Xiaoping Wang
XZXiaojie Zhang
Xiaojie Zhang
Accumulating evidence has suggested that the gut microbiome plays an important role in depression. Akkermansia muciniphila (AKK), a next-generation probiotic, shows a beneficial effect on immune and metabolic homeostasis. The relative abundance of AKK was found negatively correlated with depressive symptoms in both clinical and pre-clinical studies. To evaluate the potential antidepressant effect of AKK and explore the possible mechanism, we used chronic alcohol exposure and chronic unpredictable mild stress (CUMS) to induce depressive-like behaviors in mice. We found that oral AKK administration significantly reduced the immobility time in the force swimming test (FST) and tail suspension test (TST) in the mice with chronic alcohol exposure and the CUMS mice. The sucrose preference in the mice receiving AKK was significantly increased in the sucrose preference test (SPT). More importantly, AKK implantation significantly increased the level of 5-HT in the gut and PFC of both the alcohol exposure mice and the CUMS mice. Furthermore, AKK had inhibited the expression of SERT in the gut but not in the brain for both NIAAA and the CUMS model mice. Interestingly, the expression of cFos in enteric nerves in the gut significantly decreased after AKK administration. In conclusion, our study demonstrated the antidepressant effect of AKK in mice exposed to alcohol exposure and CUMS, with the potential mechanism that AKK implantation might lead to an increased level of 5-HT and inhibited SERT expression in the gut, and might alter the gut-to-brain signal through suppression of enteric nerves activation.

22 October 2020 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
CYCheng Yang
Cheng Yang
XFXiaoya Fu
Xiaoya Fu
WHWei Hao
Wei Hao
XXXiaojun Xiang
Xiaojun Xiang
TLTieqiao Liu
Tieqiao Liu
XZXiaojie Zhang
Xiaojie Zhang

6 October 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
XFXuan Fu
Xuan Fu
TCTi Chen
Ti Chen
JCJingda Cai
Jingda Cai
BLBo Liu
Bo Liu
YZYaohui Zeng
Yaohui Zeng
XZXiaojie Zhang
Xiaojie Zhang
Substance addiction is a complex worldwide public health problem. It endangers both personal life and social stability, causing great loss on economy. Substance-related disorder is considered to be a complicated chronic brain disorder. It resulted from interactions among pharmacological properties of addictive substances, individual susceptibility, and social–environmental factors. Unfortunately, there is still no ideal treatment for this disorder. Recent lines of evidence suggest that gut microbiome may play an important role in the pathogenesis of neuropsychiatric disorders, including substance-related disorders. This review summarizes the research on the relationship between gut microbiome and substance-related disorders, including different types of substance, different individual susceptibility, and the occurrence and development of substance-induced mental disorders. We also discuss the potentiation of gut microbiome in the treatment of substance-related disorders, especially in the treatment of substance-induced mental disorders and manipulation on individuals’ responsiveness to addictive substances.

28 August 2020 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
JZJingyuan Zhang
Jingyuan Zhang
JYJun Yang
Jun Yang
CYCheng Yang
Cheng Yang
TCTi Chen
Ti Chen
ZWZiwei Wang
Ziwei Wang
XZXiaojie Zhang
Xiaojie Zhang
Gut microbiota has been found to establish a bidirectional relationship with the central nervous system. Variations of the gut microbiota has been implicated in various mental disorders, including opioid use disorders. Morphine exposure has been repeatedly found to disrupt the gut microbiota, but association between the gut microbiota and the sensitivity to morphine reward remains unknown. In this study the conditioned place preference (CPP) paradigm was used for morphine-treated rats and saline-treated rats. After the CPP procedure, the morphine-treated rats were divided equally into the low and high CPP (L- and H-CPP) groups according to the CPP scores. We adopted 16S rRNA sequencing for the fecal bacterial communities at baseline and post-conditioning. By comparing the morphine-treated group with saline-treated group, we found alterations of microbial composition in the morphine-treated group, but no significant differences in alpha diversity. The L-CPP group and H-CPP group differed in microbial composition both before and after morphine treatment. The relative abundance of certain taxa was correlated to the CPP scores, such as Alloprevotella and Romboutsia. This study provides direct evidence that morphine exposure alters the composition of the gut microbiota in rats and that microbial alterations are correlated to the sensitivity to morphine reward. These findings may help develop novel therapeutic and preventive strategies for opioid use disorder.